Related Experiment Video
Updated: Jul 27, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review
J Sporn1, S N Ghaemi, M R Sambur
1Department of Psychiatry, Massachusetts General Hospital, USA. spornj@intra.NIMH.NIH.GOV
Objective:
To assess the effectiveness and safety of pramipexole as an adjunctive medication in refractory bipolar and unipolar depression in a naturalistic setting.
Methods:
Retrospective chart review by psychiatrists on staff at a university hospital identified all patients who had received pramipexole. Response was based on moderate to marked improvement in the Clinical Global Impression-Improvement (CGI-I) scale.
Results:
Pramipexole (mean dose 0.70 mg/d, mean duration 24.4 weeks) was effective in 6/12 (50.0%) of patients with bipolar depression, and 8/20 (40%) of patients with unipolar depression, mean duration of follow-up of 24.4 weeks. One case of transient hypomania was noted. Eight patients discontinued pramipexole due to lack of response and four due to side effects.
Conclusions:
Pramipexole, used as an adjunct to antidepressants or mood stabilizers, appeared to be effective and safe in the treatment of unipolar and bipolar depression. These uncontrolled, retrospective, naturalistic pilot data require confirmation by controlled research before conclusions can be made.
More Related Videos
Related Concept Videos
Psychosis: Goals of Pharmacotherapy
Mania and Antimanic Drugs: Overview
Antidepressant Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Therapy
Antianxiety Medications

